AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7525246 — intervention group
Group type: EXPERIMENTAL
Intervention: Analysis of ERD responses in frequency bands (8-10 Hz, 10-12 Hz, 12-20 Hz, 20-30 Hz)
Number of subjects: 23
Study 7525246 — intervention group
Group type: COMPARATOR
Intervention: Comparison of ERD response magnitude and MRCP peak amplitude
Number of subjects: 23
Study 7525246 — intervention group
Group type: EXPERIMENTAL
Intervention: Timing and topographical features of ERD responses
Number of subjects: 23
Study 3679574 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma exchange (PE) in acute idiopathic radiculopolyneuropathies
Number of subjects: 62
Study 3679574 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma exchange (PE) in chronic idiopathic radiculopolyneuropathies
Number of subjects: 62
Study 3679574 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma exchange (PE) in Guillain-Barré syndrome
Number of subjects: 62
Study 3679574 — intervention group
Group type: COMPARATOR
Intervention: Control group (12 patients)
Number of subjects: 62
Study 29343303 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified wet suction technique (MWST)
Number of subjects: 296
Study 29343303 — intervention group
Group type: COMPARATOR
Intervention: Dry suction technique (DRST)
Number of subjects: 296
Study 26340656 — intervention group
Group type: EXPERIMENTAL
Intervention: Craniosacral Therapy (CST)
Number of subjects: 54
Study 26340656 — intervention group
Group type: COMPARATOR
Intervention: Light-touch sham treatment
Number of subjects: 54
Study 25258523 — intervention group
Group type: EXPERIMENTAL
Intervention: IG/HD + RCH (210 g of ricotta cheese daily)
Number of subjects: 0
Study 25258523 — intervention group
Group type: COMPARATOR
Intervention: CG/HD (habitual diet only)
Number of subjects: 0
Study 22682721 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 200 mg orally 24 hours prior to abortion
Number of subjects: 50
Study 22682721 — intervention group
Group type: COMPARATOR
Intervention: Osmotic dilators
Number of subjects: 50
Study 20202538 — intervention group
Group type: EXPERIMENTAL
Intervention: Correction for posture-related ocular cyclotorsion
Number of subjects: 102
Study 20202538 — intervention group
Group type: COMPARATOR
Intervention: No correction for posture-related ocular cyclotorsion
Number of subjects: 102
Study 18426457 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxing classical music (Group 1)
Number of subjects: 94
Study 18426457 — intervention group
Group type: COMPARATOR
Intervention: Audiobook (Group 2)
Number of subjects: 94
Study 18426457 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control Group 3)
Number of subjects: 94
Study 15753242 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) combined with pharmacotherapy
Number of subjects: 232
Study 15753242 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 232
Study 12634260 — intervention group
Group type: EXPERIMENTAL
Intervention: Acamprosate (n = 72)
Number of subjects: 142
Study 12634260 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 70)
Number of subjects: 142
Study 11388815 — intervention group
Group type: EXPERIMENTAL
Intervention: Home service (automatic transmission of blood pressure data, computerized report forms, weekly electronic transmission)
Number of subjects: 121
Study 11388815 — intervention group
Group type: EXPERIMENTAL
Intervention: Home service
Number of subjects: 121
Study 11388815 — intervention group
Group type: EXPERIMENTAL
Intervention: Home service among African-American patients
Number of subjects: 121
Study 11388815 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 121
Study 11388815 — intervention group
Group type: COMPARATOR
Intervention: Usual care among African-American patients
Number of subjects: 121
Study 9252945 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral feeding starting on postoperative day (POD) 1 via a jejunostomy tube (FEED, n = 12)
Number of subjects: 29
Study 9252945 — intervention group
Group type: COMPARATOR
Intervention: IV fluid (IVF, n = 17)
Number of subjects: 29
Study 9252945 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral feeding (FEED)
Number of subjects: 29
Study 8233500 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine with oxymetazoline (lido/oxy)
Number of subjects: 0
Study 8233500 — intervention group
Group type: COMPARATOR
Intervention: Cocaine
Number of subjects: 0
Study 3326920 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (50 mg twice daily)
Number of subjects: 32
Study 3326920 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg twice daily)
Number of subjects: 32
Study 3326920 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril plus Nifedipine (50 mg and 20 mg twice daily respectively)
Number of subjects: 32
Study 3326920 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 31995558 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring (TM)
Number of subjects: 50
Study 31995558 — intervention group
Group type: COMPARATOR
Intervention: Conventional monitoring (CM)
Number of subjects: 50
Study 31683617 — intervention group
Group type: EXPERIMENTAL
Intervention: Yeast cell wall extract (YCWE) 0.2%
Number of subjects: 168
Study 31683617 — intervention group
Group type: COMPARATOR
Intervention: No YCWE (0%)
Number of subjects: 168
Study 28228696 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling plus Spinal Manipulation (SM)
Number of subjects: 10
Study 28228696 — intervention group
Group type: COMPARATOR
Intervention: Counseling alone (Control)
Number of subjects: 10
Study 25799208 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 937
Study 23978310 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy younger adults (N=14)
Number of subjects: 39
Study 23978310 — intervention group
Group type: EXPERIMENTAL
Intervention: Older non-fallers (N=14)
Number of subjects: 39
Study 23978310 — intervention group
Group type: EXPERIMENTAL
Intervention: Older fallers (N=11)
Number of subjects: 39
Study 23978310 — intervention group
Group type: COMPARATOR
Intervention: Older non-fallers and fallers (N=25)
Number of subjects: 39
Study 21235822 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower levels of oxygen (targeting oxygen saturations of <90%)
Number of subjects: 5000
Study 21235822 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of oxygen (targeting oxygen saturations of >90%)
Number of subjects: 5000
Study 21235822 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite outcome of death or major disability at 18 months - 2 years corrected age
Number of subjects: 5000
Study 21235822 — intervention group
Group type: EXPERIMENTAL
Intervention: Several measures of neonatal morbidity
Number of subjects: 5000
Study 19214122 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% SPL7013 gel (n = 24)
Number of subjects: 36
Study 19214122 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel (n = 12)
Number of subjects: 36
Study 19214122 — intervention group
Group type: EXPERIMENTAL
Intervention: SPL7013 gel
Number of subjects: 36
Study 17237130 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (n = 1511, target dose 50 mg daily)
Number of subjects: 3029
Study 17237130 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol (n = 1518, target dose 100 mg daily)
Number of subjects: 3029
Study 17237130 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (n = 1511)
Number of subjects: 3029
Study 17237130 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol (n = 1518)
Number of subjects: 3029
Study 17237130 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 3029
Study 17237130 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 3029
Study 15205083 — intervention group
Group type: EXPERIMENTAL
Intervention: Fe(2+)
Number of subjects: 72
Study 15205083 — intervention group
Group type: EXPERIMENTAL
Intervention: Fe(3+)
Number of subjects: 72
Study 11352444 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline 400mg alone (Treatment B)
Number of subjects: 12
Study 11352444 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline 400mg plus moxifloxacin 200mg (Treatment C)
Number of subjects: 12
Study 11352444 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 200mg alone (Treatment A)
Number of subjects: 12
Study 9797810 — intervention group
Group type: EXPERIMENTAL
Intervention: Three cycles of bleomycin, etoposide, and cisplatin (BEP) for good-risk GCTs
Number of subjects: 0
Study 9797810 — intervention group
Group type: EXPERIMENTAL
Intervention: Four cycles of etoposide and cisplatin (EP) for good-risk GCTs
Number of subjects: 0
Study 9797810 — intervention group
Group type: EXPERIMENTAL
Intervention: Four cycles of BEP for poor-risk GCTs
Number of subjects: 0
Study 9797810 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (HDCT) with autologous stem cell rescue
Number of subjects: 0
Study 9797810 — intervention group
Group type: EXPERIMENTAL
Intervention: HDCT in first-line therapy for poor-risk GCTs
Number of subjects: 0
Study 9797810 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin-resistance
Number of subjects: 0
Study 7849445 — intervention group
Group type: EXPERIMENTAL
Intervention: 900 mg aspirin daily
Number of subjects: 359
Study 7849445 — intervention group
Group type: COMPARATOR
Intervention: 50 mg aspirin daily
Number of subjects: 359
Study 3053556 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin
Number of subjects: 88
Study 3053556 — intervention group
Group type: EXPERIMENTAL
Intervention: Netilmicin
Number of subjects: 88
Study 31209337 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 28870554 — intervention group
Group type: COMPARATOR
Intervention: Conventional professional based speech language therapy (SLT) alone (Group A/less intensive)
Number of subjects: 24
Study 28870554 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional professional based speech language therapy (SLT) assisted by computer based language therapy software (Group B/more intensive)
Number of subjects: 24
Study 25986600 — intervention group
Group type: EXPERIMENTAL
Intervention: Total omega-3 PUFA intake
Number of subjects: 3550
Study 25986600 — intervention group
Group type: EXPERIMENTAL
Intervention: α-linolenic acid intake
Number of subjects: 3550
Study 25986600 — intervention group
Group type: EXPERIMENTAL
Intervention: Linoleic/α-linolenic ratio
Number of subjects: 3550
Study 23416804 — intervention group
Group type: EXPERIMENTAL
Intervention: Peppermint oil, administered three times daily for six weeks
Number of subjects: 65
Study 23416804 — intervention group
Group type: COMPARATOR
Intervention: Placebo, administered three times daily for six weeks
Number of subjects: 65
Study 21809232 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal packing with breathing tubes
Number of subjects: 73
Study 21809232 — intervention group
Group type: COMPARATOR
Intervention: Glove packing
Number of subjects: 73
Study 21809232 — intervention group
Group type: COMPARATOR
Intervention: Polyvinyl acetate packing
Number of subjects: 73
Study 19228414 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive intervention (patient and physician interventions)
Number of subjects: 279
Study 19228414 — intervention group
Group type: COMPARATOR
Intervention: Minimal intervention
Number of subjects: 279
Study 19228414 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-physician communication behaviors
Number of subjects: 279
Study 19228414 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient ratings of care
Number of subjects: 279
Study 19228414 — intervention group
Group type: EXPERIMENTAL
Intervention: Health service utilization
Number of subjects: 279
Study 19228414 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure control
Number of subjects: 279
Study 16678595 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction annuloplasty and coronary artery bypass grafting (RA group)
Number of subjects: 0
Study 16678595 — intervention group
Group type: EXPERIMENTAL
Intervention: Coapsys annuloplasty and bypass grafting (CO group)
Number of subjects: 0
Study 15673985 — intervention group
Group type: EXPERIMENTAL
Intervention: St. John's wort extract (SJW) 600 mg (standardized to contain 1800 microg of hypericin)
Number of subjects: 169
Study 15673985 — intervention group
Group type: COMPARATOR
Intervention: Placebo (containing lactose and cellulose)
Number of subjects: 169
Study 11408053 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-task performance in depressed patients prior to antidepressant treatment
Number of subjects: 2
Study 11408053 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-task performance in depressed patients after remission of depression
Number of subjects: 2
Study 11408053 — intervention group
Group type: COMPARATOR
Intervention: Dual-task performance in control subjects
Number of subjects: 2
Study 9203932 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecystokinin (CCK) at 30 ng/kg/h
Number of subjects: 10
Study 9203932 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 10
Study 9203932 — intervention group
Group type: EXPERIMENTAL
Intervention: Loxiglumide (CCK‐A receptor antagonist) at 10 mg/kg/h
Number of subjects: 10
Study 9203932 — intervention group
Group type: COMPARATOR
Intervention: Paired saline infusion
Number of subjects: 10
Study 7869908 — intervention group
Group type: EXPERIMENTAL
Intervention: Delta TSA exceeding 10 mg/dL
Number of subjects: 74
Study 7869908 — intervention group
Group type: COMPARATOR
Intervention: Delta TSA not exceeding 10 mg/dL
Number of subjects: 74
Study 7869908 — intervention group
Group type: EXPERIMENTAL
Intervention: Total sialic acid (TSA) levels
Number of subjects: 74
Study 2081793 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral immune globulin preparation
Number of subjects: 0
Study 2081793 — intervention group
Group type: COMPARATOR
Intervention: Standard infection control measures
Number of subjects: 0
Study 367576 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of vincristine, methyl‐CCNU, and methotrexate with MER‐BCG
Number of subjects: 124
Study 367576 — intervention group
Group type: COMPARATOR
Intervention: Combination of vincristine, methyl‐CCNU, and methotrexate without MER‐BCG
Number of subjects: 124
Study 367576 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of vincristine, methyl‐CCNU, and methotrexate (with or without MER‐BCG)
Number of subjects: 124
Study 31629881 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory resistive breathing (IRB) test
Number of subjects: 15
Study 31629881 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocapnic hyperpnea endurance (IHE) test
Number of subjects: 15
Study 31657981 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐asparaginase 3,500 U/m2
Number of subjects: 598
Study 31657981 — intervention group
Group type: COMPARATOR
Intervention: PEG‐asparaginase 2,500 U/m2 (control)
Number of subjects: 598
Study 31657981 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional intrathecal therapy (two extra doses)
Number of subjects: 598
Study 31657981 — intervention group
Group type: COMPARATOR
Intervention: No additional intrathecal therapy
Number of subjects: 598
Study 28089917 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,25(OH)2D
Number of subjects: 45
Study 25585167 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-chain omega-3 (ω-3) polyunsaturated fatty acids (PUFAs)
Number of subjects: 0
Study 25585167 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25406858 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual homecare re‐ablement plus an enhanced program targeted at activities of daily living (ADL), delivered by an occupational therapist.
Number of subjects: 50
Study 25406858 — intervention group
Group type: COMPARATOR
Intervention: Usual homecare re‐ablement (without routine occupational therapy input).
Number of subjects: 50
Study 22785005 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive servo-ventilation (ASV)
Number of subjects: 42
Study 22785005 — intervention group
Group type: COMPARATOR
Intervention: Oxygen therapy (O(2))
Number of subjects: 42
Study 19637377 — intervention group
Group type: EXPERIMENTAL
Intervention: tolterodine ER 4 mg
Number of subjects: 30
Study 19637377 — intervention group
Group type: EXPERIMENTAL
Intervention: tolterodine ER 8 mg
Number of subjects: 30
Study 19637377 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 30
Study 17982551 — intervention group
Group type: COMPARATOR
Intervention: Clearfil Liner Bond 2V ‐ C
Number of subjects: 40
Study 17982551 — intervention group
Group type: EXPERIMENTAL
Intervention: Prime&Bond NT/NRC ‐ PB
Number of subjects: 40
Study 17982551 — intervention group
Group type: EXPERIMENTAL
Intervention: Single Bond ‐ SB
Number of subjects: 40
Study 17982551 — intervention group
Group type: EXPERIMENTAL
Intervention: All Bond 2 ‐ AB
Number of subjects: 40
Study 16033162 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulant medication
Number of subjects: 4
Study 16033162 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study 12153960 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 400 micro g once daily (n = 13)
Number of subjects: 26
Study 12153960 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 13)
Number of subjects: 26
Study 10089948 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral fluoropyrimidines (o-FPs)
Number of subjects: 4960
Study 10089948 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 4960
Study 8777335 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncooked cornstarch in milk (Test Snack Period)
Number of subjects: 13
Study 8777335 — intervention group
Group type: COMPARATOR
Intervention: Standard Snack Period
Number of subjects: 13
Study 1847088 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate
Number of subjects: 324
Study 1847088 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium citrate
Number of subjects: 324
Study 1847088 — intervention group
Group type: COMPARATOR
Intervention: Glucose placebo
Number of subjects: 324
Study 6882723 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein-low-carbohydrate diet
Number of subjects: 6
Study 6882723 — intervention group
Group type: COMPARATOR
Intervention: High-glucose-low-protein diet
Number of subjects: 6
Study 30207807 — intervention group
Group type: EXPERIMENTAL
Intervention: HP 0.01% lotion
Number of subjects: 150
Study 30207807 — intervention group
Group type: EXPERIMENTAL
Intervention: HP 0.05% cream
Number of subjects: 150
Study 27888748 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal emotion regulation (partner's chosen strategy)
Number of subjects: 47
Study 27888748 — intervention group
Group type: COMPARATOR
Intervention: Intrapersonal emotion regulation (self-chosen strategy)
Number of subjects: 47
Study 27888748 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive empathy of the regulator
Number of subjects: 47
Study 25877021 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-mg intramuscular metoclopramide prior to operation
Number of subjects: 696
Study 22963348 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracameral mydriatics injected into the posterior chamber
Number of subjects: 44
Study 22963348 — intervention group
Group type: COMPARATOR
Intervention: Intracameral mydriatics injected into the anterior chamber
Number of subjects: 44
Study 21056445 — intervention group
Group type: EXPERIMENTAL
Intervention: Argemone mexicana (AM)
Number of subjects: 301
Study 21056445 — intervention group
Group type: COMPARATOR
Intervention: Artesunate/amodiaquine (ACT)
Number of subjects: 301
Study 21056445 — intervention group
Group type: EXPERIMENTAL
Intervention: Both AM and ACT
Number of subjects: 301
Study 21056445 — intervention group
Group type: EXPERIMENTAL
Intervention: Total parasite clearance at day 28
Number of subjects: 301
Study 19207733 — intervention group
Group type: EXPERIMENTAL
Intervention: GPi-DBS stimulation at best settings (130 Hz, high voltage)
Number of subjects: 8
Study 19207733 — intervention group
Group type: EXPERIMENTAL
Intervention: GPi-DBS stimulation at high frequency (> or = 60 Hz)
Number of subjects: 8
Study 19207733 — intervention group
Group type: EXPERIMENTAL
Intervention: GPi-DBS stimulation with varying pulse widths (60 to 450 micros)
Number of subjects: 8
Study 19207733 — intervention group
Group type: EXPERIMENTAL
Intervention: GPi-DBS stimulation at 130 Hz
Number of subjects: 8
Study 19207733 — intervention group
Group type: EXPERIMENTAL
Intervention: GPi-DBS stimulation overall
Number of subjects: 8
Study 17113691 — intervention group
Group type: EXPERIMENTAL
Intervention: Conscious analgesia and sedation during orthognathic surgery (study group).
Number of subjects: 152
Study 17113691 — intervention group
Group type: COMPARATOR
Intervention: Standard procedure without conscious analgesia and sedation (control group).
Number of subjects: 152
Study 15219269 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol adjustable maintenance dosing (two inhalations bid; stepping up to four inhalations bid if asthma worsened for a maximum of 14 days; stepping down to two inhalations once nocte or one inhalation bid if symptoms were controlled)
Number of subjects: 2358
Study 15219269 — intervention group
Group type: COMPARATOR
Intervention: Budesonide/formoterol fixed maintenance dosing (two inhalations bid)
Number of subjects: 2358
Study 11690735 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 1800 mg/day
Number of subjects: 334
Study 11690735 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 2400 mg/day
Number of subjects: 334
Study 11690735 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 334
Study 11690735 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 1800 mg/day and 2400 mg/day
Number of subjects: 334
Study 1546861 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA, 10 to 15 mg/kg body weight per day) for 6 weeks
Number of subjects: 12
Study 1546861 — intervention group
Group type: COMPARATOR
Intervention: Ursodeoxycholic acid (UDCA)
Number of subjects: 12
Study 3893793 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 20
Study 3893793 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 29538661 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) and biomarker feedback on secondhand smoke exposure (SHSe) with asthma education, MI, and SHSe feedback plus randomization to six counseling calls (MI; repeated feedback) for 4 months.
Number of subjects: 341
Study 29538661 — intervention group
Group type: COMPARATOR
Intervention: Control calls (brief check on asthma) for 4 months.
Number of subjects: 341